The Scientist Who Wouldn't Stop Shipping
In 2003, before "digital transformation" was a consulting buzzword, before SaaS was a household term, and well before any pharmaceutical executive was thinking about paperless compliance workflows, Siva Samy sat down and decided to build something the industry didn't know it desperately needed. Twenty-three years later, he's still building it - and now 30 of the top 50 life sciences companies rely on what he created.
Samy holds two titles at ValGenesis: CEO and Chief Product Strategist. Most founders hand off one or the other within a decade. Samy holds both simultaneously, and that's not an accident. It's a philosophical statement. He came out of the lab - a master's in Analytical Chemistry from the University of Madras, a Ph.D. in Medical Devices and post-doctoral work at the University of Toronto - and he built a company that runs like a scientific program: hypothesis, evidence, iteration, repeat. The product is the mission.
Before ValGenesis, Samy built his knowledge at the places that actually manufacture and test drugs and devices. He worked at Xoma, the Berkeley biotech. At 3M. At Guidant, the cardiac rhythm management company. He watched the validation process from the inside - the binders, the sign-offs, the paper trails that regulators require to prove that every drug, device, and manufacturing process performs exactly as designed. It was meticulous, crucial work. And almost all of it was being done with paper.
That's the gap Samy saw. Pharmaceutical validation is not bureaucratic box-checking. It is the formal, documented proof that a manufacturing system will consistently produce a safe and effective product. Every batch of insulin, every cardiac stent, every oncology drug depends on validation having been done correctly. Getting it wrong doesn't produce a bad quarterly result - it produces patient harm. And as of the early 2000s, most companies were managing this life-or-death process with binders and spreadsheets.
Samy built ValGenesis to be the system of record for that entire lifecycle - from initial protocol design through execution, review, approval, and ongoing monitoring. The company received the Parenteral Drug Association's New Innovative Technology Award in 2005, just two years after founding. That's a signal: the industry recognized immediately that what Samy was building was genuinely new. And ValGenesis has been recognized as the industry's first 100% end-to-end paperless validation solution.
For the first decade, growth was methodical. Samy stayed close to the customer - learning the specific workflows of pharma, biotech, and medical device organizations, building modules that mapped precisely to regulatory requirements. The platform grew into a full Validation Lifecycle Management System (VLMS), covering equipment qualification, cleaning validation, computer system validation, and more. By the early 2020s, ValGenesis had become what Samy always intended: the de facto standard.
Morgan Stanley Expansion Capital noticed. In May 2021, they put $24 million into ValGenesis - a vote of confidence from one of the most sophisticated institutional investors in growth equity. Samy used the capital to scale the sales organization, accelerate international expansion, and push into new markets across Europe and Asia-Pacific. ValConnect, the company's annual user conference, moved to Lisbon in 2024 and drew over 100 participants from three continents. The validation community had become global.
Then AI arrived - and Samy moved fast. In June 2024, ValGenesis unveiled VLMS 5.0 with industry-first AI capabilities: intelligent insights across validation activities, predictive analytics, a redesigned interface built for usability, and native support for the FDA's Computer Software Assurance (CSA) framework. A year later, in June 2025, Samy launched something more ambitious: ValGenesis Smart GxP, the first AI-enabled platform designed to unify validation and process lifecycle management under one roof. Smart GxP connects R&D through commercial manufacturing through two integrated suites - Validation Lifecycle and Process Lifecycle - with VAL, an embedded AI assistant, accelerating document generation by up to 80% and compressing review cycles from weeks to hours.
The July 2025 $16 million financing from Bridge Bank's Innovation Banking Group, backed by Morgan Stanley Expansion Capital, funded the next wave: rapid scaling of AI offerings, deeper global presence, and strategic hiring across North America, Europe, and Asia-Pacific. The market for digitized validation in life sciences is not a small one. Regulatory compliance requirements are not easing. Drug pipelines are not shrinking. And every major pharmaceutical company now understands that validation managed in binders is a liability.
Samy holds a USPTO patent titled "Validating and Maintaining Respective Validation Status of Software Applications, Manufacturing Systems and Business Processes" - a patent that captures the core logic of what ValGenesis does. He's also authored more than 15 research articles. The academic rigor that shaped his early career hasn't left; it runs through the way ValGenesis approaches product development, compliance, and customer outcomes.
In April 2026, ValGenesis launched the next generation of VAL - a governed AI system embedded across the full validation lifecycle, delivering up to 80% reduction in validation time and cost compared with manual processes. Samy is scheduled to appear at Interphex Week Tokyo in May 2026 and the ISPE Annual Meeting & Expo in October 2026. He is not done building.